SEC Filing Summary: AntriaBio, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 29, 2016, covers events occurring on June 24, 2016, and June 28, 2016. The registrant is AntriaBio, Inc., a Delaware corporation. The filing details the completion of a Private Investment in Public Equity (PIPE) financing, the conversion of Series A Preferred Stock, and the entry into material definitive agreements with placement agents.
Key Financial Metrics and Transaction Details
- Gross Proceeds: The Company received gross cash proceeds of $1.8 million from the PIPE Financing, excluding placement agent compensation and transaction costs.
- Securities Issued: An aggregate of 1,711,452 Units were issued to investors.
- Unit Pricing and Structure:
- Class A Units: Priced at $1.10 per unit; consists of one share of common stock and one-half of one warrant.
- Class B Units: Priced at $1.10 per unit; consists of one share of common stock and one full warrant (available to qualifying prior investors).
- Warrant Terms: Warrants are exercisable at $1.65 per share for a period of 60 months (5 years) following the close.
- Preferred Stock Conversion: 3,326,714 shares of Series A Preferred Stock were converted into 5,897,678 Exchange Shares and related Exchange Warrants at an exchange rate of $1.10 per share.
- Placement Agent Fees:
- First Agent: 10% cash fee on gross proceeds, 3% cash fee on warrant exercises, 10% warrant fee, and a $25,000 expense fee.
- Second Agent: 7% cash fee on gross proceeds and a 10% warrant fee.
Material Changes and Agreements
The filing reports the entry into Purchase Agreements with investors and Placement Agent Agreements. A significant capital structure change occurred with the complete conversion of Series A Preferred Stock into common stock and warrants, terminating all rights associated with the preferred shares. The Company also granted registration rights to investors and agents, agreeing to file a registration statement within 90 days of the close.
Outlook, Risks, and Contingencies
The filing does not provide specific forward-looking guidance, revenue projections, or management commentary regarding future operational performance. The primary contingency noted is the requirement to file a registration statement to allow for the resale of the issued securities. The securities were sold under Section 4(a)(2) and Rule 506 exemptions and are not registered for public sale until the registration statement becomes effective.
Key Facts for Investor Verification
- Verify the total net proceeds after deducting the 10% and 7% placement agent fees and the $25,000 expense fee.
- Confirm the dilution impact of the 1,711,452 new Units and the 5,897,678 Exchange Shares issued upon preferred stock conversion.
- Monitor the filing of the registration statement required within 90 days of the June 28, 2016 close date.
- Review the full text of the Purchase Agreements and Warrants (Exhibits 10.1, 4.1, 4.2) for specific covenants and anti-dilution provisions.